BIOMUNEX PHARMACEUTICALS

BIOMUNEX PHARMACEUTICALS is a leading biopharmaceutical company dedicated to the discovery and development of innovative immunotherapies. Using its proprietary BiXAb® technology, BIOMUNEX is creating next-generation bi- and multi-specific antibodies to target a wide range of cancer types, especially those with unmet medical needs. BIOMUNEX PHARMACEUTICALS is committed to providing oncologists and patients with novel and efficacious immunotherapies that improve and prolong life expectancy.

With headquarters in Paris, located at 113 RUE DE LA TOUR, 75116, FR, and additional locations at 1 Broadway, Cambridge, MA 02142, US, and 117 avenue Victor Hugo, Boulogne Billancourt, 92100, FR, BIOMUNEX PHARMACEUTICALS is strategically positioned to advance its research and development efforts. The company's disruptive biological approaches are focused on delivering breakthrough treatments to address critical challenges in oncology. BIOMUNEX is driven by a passion for innovation and a commitment to making a meaningful difference in the lives of patients.

BIOMUNEX PHARMACEUTICALS aims to revolutionize cancer treatment through its unique BiXAb® technology and dedication to scientific excellence. The company continually seeks to expand its capabilities and collaborations to further its mission of providing life-changing therapies. We encourage the manager of BIOMUNEX PHARMACEUTICALS to create a customized and exclusive company showcase and product listing on our platform to further enhance their visibility and commercial reach.